静脉-动脉体外膜氧合中动脉二氧化碳分压与临床结局的关联
该研究为国际体外生命支持组织登记数据的回顾性队列分析,纳入2003至2016年接受VA-ECMO的成年患者。共7168例患者有启动时动脉二氧化碳分压数据,其中4918例有24小时数据。住院死亡率为59.9%。启动时动脉二氧化碳分压与住院死亡率呈U型关系:低于30 mm Hg(OR 1.26,95%CI 1.08-1.47,P=0.003)和高于60 mm Hg(OR 1.28,95%CI 1.10-1.50,P=0.002)均与死亡率增加相关。24小时内动脉二氧化碳分压大幅下降(>20 mm Hg)与颅内出血、缺血性卒中或脑死亡复合结局相关(OR 1.63,95%CI 1.03-2.59,P=0.04),且独立于初始动脉二氧化碳分压。作者认为需要进一步的前瞻性研究验证这些关联。
要点
- VA-ECMO启动时动脉二氧化碳分压与住院死亡率呈U型关联,低于30 mm Hg或高于60 mm Hg均与死亡率增加相关。
- 启动时动脉二氧化碳分压<30 mm Hg者住院死亡风险增加(OR 1.26,95%CI 1.08-1.47,P=0.003)。
- 启动时动脉二氧化碳分压>60 mm Hg者住院死亡风险增加(OR 1.28,95%CI 1.10-1.50,P=0.002)。
- 24小时内动脉二氧化碳分压下降>20 mm Hg与颅内出血、缺血性卒中或脑死亡复合结局相关(OR 1.63,95%CI 1.03-2.59,P=0.04)。
- 该关联独立于初始动脉二氧化碳分压,提示ECMO运行中二氧化碳分压管理可能影响神经系统结局。
适用人群与场景
- 成人患者(≥18岁)接受静脉-动脉体外膜氧合(VA-ECMO)治疗,适应证为心脏骤停和难治性心源性休克。
- 数据来源于2003-2016年国际体外生命支持组织登记的所有国际ECMO中心。
研究设计与关键结果
- 研究类型:回顾性队列分析,使用国际体外生命支持组织登记数据,纳入2003-2016年接受VA-ECMO的成人患者。
- 共7168例患者有VA-ECMO启动时动脉二氧化碳分压数据,其中4918例有24小时数据;总住院死亡率为59.9%。
- 启动时动脉二氧化碳分压与住院死亡率呈U型关系:<30 mm Hg者OR 1.26(95%CI 1.08-1.47,P=0.003),>60 mm Hg者OR 1.28(95%CI 1.10-1.50,P=0.002)。
- 24小时内动脉二氧化碳分压下降>20 mm Hg与颅内出血、缺血性卒中或脑死亡复合结局相关(OR 1.63,95%CI 1.03-2.59,P=0.04),独立于初始动脉二氧化碳分压。
证据类型、等级与局限
- 证据类型:回顾性队列分析(基于国际登记数据库)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,VA-ECMO启动时动脉二氧化碳分压与住院死亡率独立相关,24小时内动脉二氧化碳分压下降>20 mm Hg与神经系统并发症相关;进一步的前瞻性研究验证这些关联是必要的。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The manipulation of arterial carbon dioxide tension is associated with differential mortality and neurologic injury in intensive care and cardiac arrest patients; however, few studies have investigated this relationship in patients on venoarterial extracorporeal membrane oxygenation. We investigated the association between the initial arterial carbon dioxide tension and change over 24 hours on mortality and neurologic injury in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiac arrest and refractory cardiogenic shock.
DESIGN: Retrospective cohort analysis of adult patients recorded in the international Extracorporeal Life Support Organization Registry.
SETTING: Data reported to the Extracorporeal Life Support Organization from all international extracorporeal membrane oxygenation centers during 2003-2016.
PATIENTS: Adult patients (≥ 18 yr old) supported with venoarterial extracorporeal membrane oxygenation.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: A total of 7,168 patients had sufficient data for analysis at the initiation of venoarterial extracorporeal membrane oxygenation, 4,918 of these patients had arterial carbon dioxide tension data available at 24 hours on support. The overall in-hospital mortality rate was 59.9%. A U-shaped relationship between arterial carbon dioxide tension tension at extracorporeal membrane oxygenation initiation and in-hospital mortality was observed. Increased mortality was observed with a arterial carbon dioxide tension less than 30 mm Hg (odds ratio, 1.26; 95% CI, 1.08-1.47; p = 0.003) and greater than 60 mm Hg (odds ratio, 1.28; 95% CI, 1.10-1.50; p = 0.002). Large reductions (> 20 mm Hg) in arterial carbon dioxide tension over 24 hours were associated with important neurologic complications: intracranial hemorrhage, ischemic stroke, and/or brain death, as a composite outcome (odds ratio, 1.63; 95% CI, 1.03-2.59; p = 0.04), independent of the initial arterial carbon dioxide tension.
CONCLUSIONS: Initial arterial carbon dioxide tension tension was independently associated with mortality in this cohort of venoarterial extracorporeal membrane oxygenation patients. Reductions in arterial carbon dioxide tension (> 20 mm Hg) from the initiation of extracorporeal membrane oxygenation were associated with neurologic complications. Further prospective studies testing these associations are warranted.
参考来源
- Diehl A, Burrell AJC, Udy AA, et al. Association Between Arterial Carbon Dioxide Tension and Clinical Outcomes in Venoarterial Extracorporeal Membrane Oxygenation. Crit Care Med. 2020. PMID: 32574466. doi:10.1097/CCM.0000000000004347
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。